MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2147/lctt.s631512

Медицинская библиотека · Lung Cancer (Auckland, N.Z.) · 2026

Tiered Group of Disease Driven Oncogene Informs Survival Outcome of Taiwanese and Japanese Patients with Advanced NSCLC in the LC-SCRUM-Asia Study.

Kuo Chih-Hsi Scott, Umemura Shigeki, Wang Chin-Chou, Matsumoto Shingo, Ko How-Wen, Chung Fu-Tsai, Hsu Ping-Chih, Izumi Hiroki, Shibata Yuji, Udagawa Hibiki, Yoh Kiyotaka, Murata Yuri, Goto Koichi, Yang Cheng-Ta

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Targeted therapy improves survival of oncogene-driven NSCLC. We evaluate the clinical outcome of advanced NSCLC with oncogenic drivers in LC-SCRUM-Asia Taiwanese and Japanese cohort using tiered groups of disease-driven oncogene.

METHODS

Fourteen genes were reported from NGS and grouped into four tiers based on lines of approved targeted therapies in Taiwan and Japan (Tier 1: ≥ two lines; Tier 2: one line; Tier 3: not targetable; Tier 4: potentially targetable; not yet approved). Overall survival (OS) of the four-tier gene groups was analyzed in Taiwanese cohort and validated in the 8619 Japanese patients using a two-stage approach.

RESULTS

Three-hundred-fifty-nine patients were enrolled in Taiwanese cohort, of which 249 (69.4%) patients had a reported genomic alteration. Patients with a history of smoking (HR 0.46 [95% CI, 0.23-0.92]; p=0.031) and squamous cell carcinoma (HR 0.31 [95% CI, 0.12-0.78]; p=0.014) had a lower incidence of genomic alterations. The top five genomic alterations were EGFR (44.6%), KRAS (7.2%), ALK (3.9%), MET (3.1%) and ERBB2 (2.5%) mutations. The four-tier gene groups were significantly associated with different OS in Taiwanese patients (Log rank test p < 0.001). The adjusted OS was the longest and the shortest in patients with Tier 1 (34.5 months) and Tier 4 (16.6 months) gene groups, respectively. In Japanese cohort, a similar trend between the four-tier gene groups and OS was observed (Log rank test p < 0.001) where the Tier 1 and the Tier 4 gene groups also demonstrated the longest (42.6 months) and the shortest OS (18.9 months), respectively.

CONCLUSION

The available lines of targeted therapy impact survival in patients of advanced oncogene-driven NSCLC.

Для цитирования: Kuo Chih-Hsi Scott, Umemura Shigeki, Wang Chin-Chou, Matsumoto Shingo, Ko How-Wen, Chung Fu-Tsai, Hsu Ping-Chih, Izumi Hiroki, Shibata Yuji, Udagawa Hibiki, Yoh Kiyotaka, Murata Yuri, Goto Koichi, Yang Cheng-Ta. Tiered Group of Disease Driven Oncogene Informs Survival Outcome of Taiwanese and Japanese Patients with Advanced NSCLC in the LC-SCRUM-Asia Study.. Lung Cancer (Auckland, N.Z.). 2026. DOI: 10.2147/lctt.s631512.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.